CAPITULO 1.2. Conceptualización de las variables de la investigación
1.2.4 El burnout y la relación con el apoyo social
The rapid test of FFN in the cervicovaginal secretions of women presenting with symptoms of preterm labour between 28 and before 36 weeks’ gestation at the Lagos Island Maternity
Hospital is useful in predicting patient without genuine preterm labour. As such, recommending fetal fibronectin test to patient presenting with signs and symptoms of preterm labour will be a useful adjunct in the assessment of patients with suspected preterm labour.
42 REFERENCES
1. Phillip .B. Preterm labour. In: Dewhurst’s Textbooks of Obstetrics and Gynaecology for post-graduates, 8th ed. Edmonds DK. Blackwell Scientific Publication. 2012; p. 341-6.
2. Ashley SR. Late pregnancy complications. In: Current Obstetrics and Gynaecologic Diagnosis & Treatment. 11th ed. Lange Medical Books/McGraw-Hill. 2013; p. 250-3.
3. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bulletin of the World Health Organization 2010;88:31-8. doi:
10.2471/BLT.08.062554
4. Tucker J, McGuire W. Epidemiology of preterm birth. BMJ 2004;329:675-8.
5. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84.
6. Wright VC, Chang J, Jeng G, Macaluso M. Assisted reproductive technology surveillance United States, 2003. MMWR Surveill Summ. 2006;55(4):1–22.
7. Reynolds MA, Schieve LA, Martin JA, Jeng G, Macaluso M. Trends in multiple births conceived using assisted reproductive technology, United States, 1997–2000.
Pediatrics. 2003;111:1159–1162.
8. Suleiman BM, Mokuolu OA, Adesiyun OO, Adeniyi A. Pattern of perinatal mortality in babies delivered at the university of ilorin teaching hospital, ilorin, Nigeria. West Afr J Med. 2012 Mar-Apr;31(2):102-8. PubMed PMID: 23208479.
9. Petrou S. The economic consequences of preterm birth during the first 10 years of life.
BJOG 2005; 112: 10-5.
10. Honest H, Forbes CA, Duree KH, Norman G, Duffy SB, Tspourapas A, et-al. Screening to prevent spontaneous birth; Systematic reviews of accuracy and effectiveness literature with economic modeling. Health Technol Assess 2009;13(43):334
43
11. Herbst A, Nilsson C. Diagnosis of early preterm labour. BJOG 2006;113(Suppl 3):S60-7.
12. Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003;101:402-12.
13. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review.
BMJ 2002;325:301
14. Bittar RE, Yamasaki AA, Sasaki S, Zugaib M. Cervical fetal fibronectin in patients at increased risk for preterm delivery. Am J Obstet Gynecol 1996; 175:178.
15. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, McNellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol. 1996 ;87(5):643-8 16. ACOG practice bulletin no. 127: management of preterm labor. Obstet Gynecol
2012;119:1308-17.
17. Use of cervical fetal fibronectin and phosphorylated insulin-like growth factor binding protein 1 as screening tests for preterm birth. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. College Statement: C-Obs 26. 2011.
18. Olugbenga AM, Suleiman BM, Adesiyan OO, Adeniyi A. prevalence and determinant of preterm deliveries in university of Ilorin teaching hospital, Ilorin, Nigeria. Paediatrics Report. 2010 june 18; 2(1). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094003/
19. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, Mathews TJ.
National Vital Statistics reports. No 7. vol 57. Hyatsville, MD: National Center for Health Statistics; 2009. Births: final data for 2006.
44
20. Ibekwe P C, Ugboma H U, Onyire N, Muoneke U. Perinatal mortality in Southern
Nigeria; Less than half a decade to the millennium developmental goals. Ann Med Health Sci Res 2011;1:215-22
21. Olamijulo JA, Olaleye O. Perinatal mortality in Lagos University Teaching Hospiatal: A five year review. Nig Q J Hosp Med. 2011 Oct-Dec;21(4):255-61
22. Crowley P. Prophylactic corticosteroids for preterm labour. Cochrane database syst rev 2006; 3:CD000065.
23. American College of Obstetricians and Gynecologists Committee on Obstetric Practice.
ACOG Committee Opinion No. 402: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2008;111(3):805–807.
24. Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM.
Tocolytic therapy: a meta-analysis and deision analysis. Obstet Gynecol.
2009;113(3):585–594.
25. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;(3):CD004454.
26. Murphy KE, Willan AR, Hannah ME, et al. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol 2012;119:917-23.
27. Eriksson L, Haglund B, Ewald U, Odlind V, Kieler H. Short and long-term effects of antenatal corticosteroids assessed in a cohort of 7,827 children born preterm. Acta Obstet Gynecol Scand. 2009;88(8):933-8.
28. Spinillo A1, Viazzo F, Colleoni R, Chiara A, Maria Cerbo R, Fazzi E. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol. 2004 Jul;191(1):217-24.
45
29. National Institutes of Health Consensus Development Conference. The effect of antenatal steroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994 Feb 28-Mar 2;12(2)1-24.
30. De Heus R, Mol BW, Erwich JJ, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009; 338:b744.
31. Berghella V, Hayes E, Visintine J, Baxter JK. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst Rev. 2008; 4:CD006843.
32. Ascarelli MH, Morrison JC. Use of fibronectin in clinical practice. Obstet Gynecol surv 1997;52(suppl 4):S1-12.
33. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN, et-al. Fetal
fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991; 325(10):669-74.
34. Morgan MA, Goldenberg RL, Schulkin J. Obstetrician-Gynecologist’ knowledge of preterm birth frequency and risk factors. J Matern Fetal Neonatal 2007;20(12):895-901.
35. Dutta D, Norman JE. The efficacy of fetal fibronectin testing in minimising hospital admissions, length of hospital stay and cost savings in women presenting with symptoms of pre-term labour. J Obstet Gynaecol 2010;30:768-73.
36. Medical Services Advisory committee (MSAC). Fetal fibronectin test for predicting preterm labour: MSAC application 1103. Assessment report 2006 Camberra: Available from: http://www.health.gov.au/internet/main/Publishing.nsf/Content/404Ref.htm.
37. Institute of health Economics (IHE). Using fetal fibronectin to diagnose preterm labour.
Edmonton, Canada: IHE, 2008.
38. Conde-Agudelo A, Romero R. J Matern Fetal Neonatal Med. 2010 Dec;23(12):1365-76.
46
39. Sanchez-Ramos L, Delke I, Zamora J, Kaunitz AM. Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis. Obstetrics and Gynecology 2009; 114(3): 631-640
40. Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol 2004;191:235-40.
41. Lowe MP, Zimmerman B, Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labor management in a tertiary care center. Am J Obstet Gynecol 2004;190:358-62.
42. Plaut MM, Smith W, Kennedy K. Fetal fibronectin: the impact of a rapid test on the treatment of women with preterm labor symptoms. Am J Obstet Gynecol 2003;188:1588-93; discussion 1593-5.
43. Ness A, Visintine J, Ricci E, Berghella V. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened preterm labor? A randomized trial. Am J Obstet Gynecol 2007;197:426.e1-7.
44. Vis JY, Wilms FF, Oudijk MA, et al. Why were the results of randomized trials on the clinical utility of fetal fibronectin negative? A systematic review of their study designs.
Am J Perinatol 2011;28:145-50.
45. Adeniji AO, Olayemi O, Odukogbe AA, Oladokun A, Adeniji OI, Egbewale
BE, Omigbodun AO. Cervico-vaginal foetal fibronectin: a predictor of cervical response at pre-induction cervical ripening. West Afr J Med. 2005 Oct-Dec;24(4):334-7.
46. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2007;(1):CD000262.
47
47. Ramsey PS, Andrews WW. Biochemical predictors of preterm labor: fetal fibronectin and salivary estriol. Clin Perinatol. 2003 Dec;30(4):701-33
48. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human
Development Maternal Fetal Medicine Unit Network. N Engl J Med. 1996;334(9):567–
572.
49. Owen J. Evaluation of the cervix by ultrasound for the prediction of preterm birth. Clin Perinatol. 2003;30(4):735–755.
50. Iams JD, Romero R, Creasy RK. Preterm labor and birth. In: Creasy RK, Resnik R, Iams JD, eds. Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice. 6th ed.
Philadelphia, Pa.: Saunders/Elsevier; 2009:559.
51. Gomez R, Romero R, Medina L, et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005;192:350-9.
52. Hincz P, Wilczynski J, Kozarzewski M, Szaflik K. Two-step test: the combined use of fetal fibronectin and sonographic examination of the uterine cervix for prediction of preterm delivery in symptomatic patients. Acta Obstet Gynecol Scand 2002;81:58-63.
53. Deshpande SN, van Asselt ADI, Tomini F, Armstrong N, Allen A, Noake C, et al. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. Health Technol Assess 2013;17(40).
48
54. Lukes AS, Thorp JM Jr, Eucker B, Pahel-Short L. Predictors of positivity for fetal fibronectin in patients with symptoms of preterm labor. Am J Obstet Gynecol.
1997;176(3):639–641.
55. Federal Republic of Nigeria Official Gazette 15 May 2007. Legal Notice on Publication of the Details of the Breakdown of the National and State Provisional Totals 2006 Census (PDF). [Accessed December 20 2008].
56. Araoye MO, Sample Size determination. In: Araoye MO (ed) research methodology with statistics for health and social sciences. Nathadex publishers, 2003, 6. 1: 115-121.
57. Cheung KW, Ngu SF, Lee CP. Fetal fibronectin test on Chinese women with symptoms of preterm labour: a pilot study. Hong Kong Med J 2013;19:424-8
58. Amanda S, Patrick St. Louis, Neda A, Marie-France D, Sayrin L. The Evaluation of the Fetal Fibronectin Test for Prediction of Preterm Delivery in Symptomatic Patients. J Obstet Gynaecol Can 2006;28(3):206–213
59. Iams JD, Casal D, McGregor JA, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995;173:141-5.
60. Peaceman AM, Andrews WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997;177:13-8.
61. Gibbs RS, Romero R, Hillier SL, Eschenbach DA, Sweet RL. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992:166:1515–28.
62. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Statement Feb 28–March 2, 194: 12(2):1–24.
49 Appendix: B
PROFORMA Serial nos:
1. Reg nos
2. Date of recruitment ……….
3. Contact phone number………..
4. Age of patient:
5. Parity:
6. Gestational age:
7. Previous history of preterm labour YES NO 8. Presenting symptom ( tick if present)
Symptoms Frequency/Presence
Uterine contractions Low backache Vaginal bleeding
Abdominopelvic Cramps Pelvic pressure
9. Fever ( ), Dysuria ( ), Frequency ( )
10. Other symptoms if present ………..
11. Membrane status Intact Ruptured 12. Cervical os dilatation at examination………
13. Any co-morbid condition (mention)………...
14. Vagina examination in last 24hours YES NO
50
15. Sexual intercourse in last 24hours YES NO 16. Transvaginal ultrasound in last 24hours YES NO 17. Use of vagina lubricant or disinfectant YES NO 18. Presence of cerclarge YES NO 19. Was patient admitted YES NO
20. Number of days on admission (if yes to question 19)……….
OUTCOME 21. Result of rapid fibronectin test………
22. Date of delivery………
23. Birth weight………..
24. Apgar score at delivery in 1st and 5th minute if delivery ensues:
25. Admission into neonatal intensive care unit (NICU) YES NO 26. No of days on admission into NICU………
27. Baby’s condition on discharge ………..
51 Appendix C: Consent form
A Prospective cohort study on the role of cervico-vaginal fetal fibronectin as a predictor of preterm labour among pregnant women at the Lagos Island Maternity Hospital, Lagos.
CONSENT FORM
I, __________________________________________________ voluntarily consent to participate in the above named research being conducted by Dr. H.A. Agbetoba of the department of obstetrics and gynaecology, Lagos island maternity hospital, Lagos.
I have been provided with the following information:
1. That the research is undertaken to determine the presence of fetal fibronectin in my vagina secretion.
2. That the sample will be collected with a swab in my vagina.
3. That my participation in this research will be at no cost to me.
4. That the research does not expose me to any risk
5. That the information generated from this study is for the purpose of research only.
6. That the information received from me will be treated with strict confidentiality.
7. That i have the right to ask questions on the aspect of the study that is not clear to me before my participation
8. That I am guaranteed the right to withdraw from the study at any time and this will not affect the care I receive at the hospital.
………. ………..
Name of participant Signature/thumbprint of participant and date
………. ………
Name of witness Signature/thumbprint of witness and date
52
Appendix D: Photomicrograph of fibronectin Rapid Test Kit
Appendix E
Test kit
Rapid FFN Cassette
Cotton swab
Extraction buffer Sample application well